Gilead Moves On From Selonsertib, Looks To ATLAS To Map Its NASH Future

12 Nov 2019

Gilead detailed its Phase III failure with ASK1 inhibitor selonsertib in NASH, but anticipates finding a new regimen to take into Phase III in NASH with the ATLAS combination study data expected in December.

Gilead, Liver Meeting stage — Gilead presents the full Phase III dataset for selonsertib at AASLD 2019

Even though the STELLAR 3/STELLAR 4 trials of Gilead Sciences Inc.’s non-alcoholic steatohepatitis (NASH) candidate selonsertib failed to show a reduction in fibrosis, the company calls the studies a valuable learning tool that will inform its continuing work on bringing a NASH drug to market – and will augment the Phase III data coming soon from the ATLAS study of the firm’s other NASH candidates.

“The results weren’t what we were hoping for, but I think it’s an extremely rich resource in terms of serum...